ℹ️
Key Fact: Human Papillomavirus (HPV) causes >99% of cervical cancers. HPV 16 causes squamous cell carcinoma (most common type) and HPV 18 causes adenocarcinoma. These are the most oncogenic HPV strains.
🦠
HPV and Oncogenesis
- HPV is a DNA virus; >100 strains; ~40 are sexually transmitted
- High-risk strains: 16, 18, 31, 33, 45 (cause cancer)
- Low-risk strains: 6, 11 (cause genital warts)
- HPV 16 = squamous cell carcinoma (70% of cervical cancers)
- HPV 18 = adenocarcinoma (more aggressive, harder to screen)
- Most HPV infections clear spontaneously within 2 years
- Persistent HPV infection → CIN → invasive cancer (10-20 years)
🔬
Cervical Intraepithelial Neoplasia (CIN)
CIN = pre-cancerous changes in transformation zone:
- CIN 1 — mild dysplasia; lower 1/3 epithelium; watchful waiting (60-70% regress)
- CIN 2 — moderate dysplasia; lower 2/3; treat with LLETZ
- CIN 3 — severe dysplasia/carcinoma in situ; full thickness; LLETZ mandatory
LLETZ = Large Loop Excision of the Transformation Zone (preferred treatment for CIN 2-3)
💉
Prevention — HPV Vaccination
- Gardasil 9 (9-valent) — protects against HPV 6, 11, 16, 18, 31, 33, 45, 52, 58
- Recommended ages: 9-26 years (most effective before sexual debut)
- Up to age 45 in shared clinical decision-making
- 2-dose schedule if started before age 15
- 3-dose schedule if started age 15+
- Screening still required even after vaccination
Cervical Screening Programmes
| Method | Frequency | Age Group | Notes |
|---|
| Pap smear (cytology) | Every 3 years | 25-64 years | Traditional; detects abnormal cells |
| HPV primary testing | Every 5 years | 25-64 years | More sensitive than cytology alone |
| Co-testing (HPV + cytology) | Every 5 years | 30-65 years | US guideline preference |
| HPV-positive + normal cytology | Repeat in 12 months | Any | If HPV persists → colposcopy |
🚨
Classic Presentation: Post-coital bleeding (PCB) is the CLASSIC symptom of cervical cancer. Any woman presenting with post-coital bleeding must have urgent cervical assessment. Early cervical cancer is often asymptomatic — this is why screening is critical.
🩸
Clinical Symptoms
Early disease:
- Often asymptomatic (detected by screening)
- Post-coital bleeding — CLASSIC symptom
- Intermenstrual bleeding
- Offensive vaginal discharge
Late / Advanced disease:
- Pelvic pain
- Dyspareunia (painful intercourse)
- Haematuria (bladder invasion)
- Rectal bleeding (rectal invasion)
- Leg oedema (lymph node obstruction)
- Back pain (ureteric obstruction, hydronephrosis)
📊
FIGO Staging (2018)
- Stage I — Confined to cervix only
- Stage IA — Microscopic invasion (<5mm depth)
- Stage IB — Clinically visible lesion, confined to cervix
- Stage IIA — Upper vagina involved, no parametrial invasion
- Stage IIB — Parametrial invasion present
- Stage IIIA — Lower vagina involved
- Stage IIIB — Pelvic wall or hydronephrosis
- Stage IVA — Bladder or rectal mucosa involved
- Stage IVB — Distant metastases
🔬
Investigations
- Colposcopy — visualisation of transformation zone with acetic acid/Schiller's test
- Cervical biopsy — definitive histological diagnosis
- MRI pelvis — local staging (parametrial invasion, lymph nodes)
- CT chest/abdomen/pelvis — distant metastasis
- PET-CT — most sensitive for nodal and distant disease
- EUA (Examination Under Anaesthesia) — bladder/rectal involvement
⚠️
Risk Factors
- Early sexual debut (<16 years)
- Multiple sexual partners
- High-risk partner
- Immunosuppression (HIV, transplant patients)
- Smoking (2× risk — impairs local immune response)
- OCP use >5 years (modest increase)
- High parity (cervical trauma)
- Non-attendance at screening
- Previous CIN or STI history
| Stage | Primary Treatment | Notes |
|---|
| CIN 1 | Watchful waiting (colposcopy at 12 months) | 60-70% regress spontaneously |
| CIN 2-3 | LLETZ (Large Loop Excision of Transformation Zone) | Clear margins essential; follow-up HPV testing |
| Stage IA1 | Simple hysterectomy or cone biopsy (fertility sparing) | Microinvasive only |
| Stage IB-IIA | Radical hysterectomy (Wertheim's) + lymph node dissection OR chemoradiation | Equivalent outcomes; surgery preferred if young |
| Stage IIB-IVA | Concurrent chemoradiation (cisplatin + external beam radiotherapy + brachytherapy) | Chemoradiation is standard of care |
| Stage IVB | Palliative cisplatin-based chemotherapy ± bevacizumab | Pembrolizumab for PD-L1 positive recurrent disease |
🔪
Radical Hysterectomy (Wertheim's)
- Removes uterus, cervix, upper vagina, parametrium, and pelvic lymph nodes
- Suitable for Stage IB-IIA in fit patients
- Pre-operative counselling: future fertility will be lost
- Ovaries may be conserved in young women (not invaded)
- Complications: bladder dysfunction, lymphoedema, sexual dysfunction
⚡
Chemoradiation Protocol
- Cisplatin — weekly IV, radiosensitiser
- External beam radiotherapy (EBRT) — 45-50 Gy in 25 fractions
- Brachytherapy — internal radiation; boosts dose to cervix/vaginal vault
- Total treatment: 5-6 weeks
- Monitor: CBC weekly (cisplatin → bone marrow suppression)
- Hydration essential: cisplatin → nephrotoxicity
⚠️
Nursing Point — Cisplatin Toxicity: Cisplatin causes nephrotoxicity, ototoxicity, peripheral neuropathy, and severe nausea/vomiting. Pre-hydration with IV saline is mandatory. Monitor creatinine and eGFR before each cycle. Antiemetics (ondansetron + dexamethasone + aprepitant) required.
🌍
GCC Context: Cervical cancer incidence is lower in GCC countries compared to global averages, partly due to lower rates of multiple sexual partners and HPV vaccine programmes. However, cultural barriers to screening and late presentation remain significant challenges for nurses to address.
💉 HPV Vaccination Programmes in GCC ▼
- UAE (DHA/DOH) — HPV vaccination included in national immunisation schedule; targeting school-age girls (age 11-12)
- Saudi Arabia (MOH) — HPV vaccine available; national rollout ongoing for adolescent girls
- Qatar (MOH) — Gardasil 9 introduced into national programme
- Bahrain, Kuwait, Oman — varying availability; increasing uptake through school health programmes
Nursing role: Vaccine education, address vaccine hesitancy, counsel parents that vaccine does not encourage sexual activity, remind patients that screening is still required even after vaccination.
🤫 Cultural Barriers to Cervical Screening ▼
- Pelvic examination is culturally sensitive — many GCC women will only accept examination by a female clinician
- Stigma around discussions of sexual health and HPV (sexually transmitted) — patients may refuse to discuss or feel shame
- Lack of awareness that cervical cancer can be prevented through screening
- Female family members may discourage screening attendance
- Expatriate workers may not access screening due to cost or unfamiliarity with local health system
Nursing strategies:
- Ensure female provider for all gynaecological examinations
- Provide health education in Arabic and other relevant languages
- Frame HPV as a virus (not a lifestyle label) — comparable to catching a cold
- Involve community health outreach, especially in mosques and schools
🌙 Ramadan Considerations ▼
- Routine cervical screening appointments can be scheduled outside Ramadan hours or around fasting — there is no fasting-related contraindication to Pap smear/HPV testing
- Chemotherapy cycles (cisplatin) should ideally be completed before Ramadan or adjusted with oncologist guidance — maintaining hydration during cisplatin is difficult during daylight fasting
- Patients undergoing pelvic radiotherapy during Ramadan should be supported to maintain adequate hydration during non-fasting hours
- Religious scholars (fatwa) generally permit medical treatments during Ramadan when medically necessary
🏥 GCC Healthcare System & Nursing Role ▼
- Nurses as health educators in community settings — primary prevention through HPV vaccine uptake counselling
- Gynaecological oncology units at Sheikh Khalifa Medical City (Abu Dhabi), King Faisal Specialist Hospital (Riyadh), HMC (Qatar), and King Hussein Cancer Centre (Jordan, serving GCC patients)
- DHA and DOH-accredited screening clinics offer cervical smear services
- Cancer care navigators increasingly important role — nurses coordinate multi-disciplinary team communication
- Palliative care nursing for advanced cervical cancer increasingly formalised across GCC
⭐
High-Yield Exam Points
- HPV causes >99% of cervical cancers
- HPV 16 = squamous; HPV 18 = adenocarcinoma
- Post-coital bleeding = CLASSIC presentation
- CIN 1 = watchful waiting; CIN 2-3 = LLETZ
- Stage IB-IIA = radical hysterectomy OR chemoradiation
- Stage IIB+ = chemoradiation (cisplatin + RT)
- Gardasil 9 = 9-valent; ages 9-26
- Screening still needed even post-vaccination
- Vaginal dilators post-radiotherapy = prevents stenosis
🚩
Common Exam Traps
- Do NOT confuse CIN 1 management (watchful waiting) with CIN 2-3 (LLETZ required)
- Early cervical cancer is often asymptomatic — do NOT say "no symptoms = no disease"
- Post-coital bleeding = urgent referral, NOT reassurance
- Chemoradiation = Stage IIB+, NOT Stage IA
- Bladder dysfunction post radical hysterectomy = teach CISC (clean intermittent self-catheterisation)
- Vaginal stenosis = late radiation complication; manage with dilators and topical oestrogen
Practice MCQs — Cervical Cancer
Q1. A 28-year-old woman presents with 3 months of post-coital bleeding. Colposcopy-directed biopsy reveals CIN 3. Which is the MOST appropriate immediate management?
A. Watchful waiting with repeat colposcopy in 12 months
B. Large Loop Excision of the Transformation Zone (LLETZ)
C. Immediate radical hysterectomy
D. Cryotherapy to transformation zone
Correct: B. CIN 3 (severe dysplasia/carcinoma in situ) requires definitive treatment with LLETZ to achieve clear margins and prevent progression to invasive carcinoma. Watchful waiting is only appropriate for CIN 1. Radical hysterectomy is not indicated for CIN 3 (pre-invasive disease).
Q2. A 42-year-old woman is diagnosed with FIGO Stage IIB cervical cancer (parametrial invasion confirmed on MRI). What is the standard first-line treatment?
A. Radical hysterectomy (Wertheim's procedure) alone
B. Palliative chemotherapy with bevacizumab
C. Concurrent chemoradiation — cisplatin with external beam radiotherapy and brachytherapy
D. Neoadjuvant chemotherapy followed by surgery
Correct: C. FIGO Stage IIB (parametrial involvement) and above is treated with concurrent chemoradiation — weekly cisplatin as a radiosensitiser combined with external beam radiotherapy (EBRT) followed by intracavitary brachytherapy. Surgery is not appropriate once the parametrium is involved.
Q3. A nurse is educating a 16-year-old girl and her mother about the HPV vaccine. The mother asks whether her daughter will still need cervical smears after vaccination. What is the CORRECT response?
A. No — Gardasil 9 prevents all HPV strains, so screening is no longer necessary
B. No — the vaccine provides 100% protection against cervical cancer
C. Yes — cervical screening is still required as Gardasil 9 does not cover all oncogenic HPV strains, and the vaccine does not treat existing HPV infections
D. Only if she has multiple sexual partners in the future
Correct: C. Gardasil 9 covers 9 HPV strains (including 16 and 18) but does not cover all high-risk strains. It also provides no protection against HPV infections already present at time of vaccination. Regular cervical screening remains essential throughout a woman's life, regardless of vaccination status.
Q4. Three months after completing pelvic radiotherapy for cervical cancer, a 38-year-old woman reports dyspareunia and difficulty with sexual intercourse. Examination reveals vaginal narrowing. What is the MOST appropriate nursing intervention?
A. Refer for immediate re-staging MRI to exclude recurrence
B. Educate on regular use of vaginal dilators and topical oestrogen cream
C. Advise complete sexual abstinence for 12 months post-radiotherapy
D. Prescribe systemic HRT immediately
Correct: B. Vaginal stenosis is a recognised late complication of pelvic radiotherapy. Regular use of vaginal dilators (starting 4-6 weeks post-radiotherapy) prevents progressive stenosis. Topical vaginal oestrogen reduces dryness and atrophy. This is a standard part of post-radiotherapy nursing follow-up for cervical cancer patients.